United Therapeutics (NASDAQ: UTHR) reported Q4 EPS of $2.67, $2.05 worse than the analyst estimate of $4.72. Revenue for the quarter came in at $491.5 million versus the consensus estimate of $519.21 million.

For earnings history and earnings-related data on United Therapeutics (UTHR) click here.